Prostate cancer - Goserelin

Prostate cancer is one of the most common cancers worldwide and the leading cancer in men in Europe and North America.

Hormonal therapy with LHRH analogues is one of the standard treatments for prostate cancer, blocking the hormones that can cause the cancer to grow. Similarly, in gynecological indications such as endometriosis or fibro-myomas, LHRH analogues can suppress the hormones responsible for abnormal tissue growth, prior to surgical removal, or just before natural menopause.

Ambrilia has developed novel formulations of the 3.8mg (1-month depot) and 10.8mg (3-month depot) versions of Zoladex® (goserelin), a Luteinizing Hormone-Releasing Hormone (LHRH) analogue indicated for hormone-sensitive prostate cancer and several gynecological indications such as fibro-myomas and endometriosis. Ambrilia’s goserelin formulations are also injectable depot formulations.

Clinical development

A Phase I/II clinical program for the 3-month formulation in prostate cancer patients is ongoing.

Licensing opportunities

Ambrilia’s proprietary Goserelin formulation is available for licensing. For more information, please contact:

Daniel Böck, Ph.D.
Vice-President, Business Development and Licensing
Tel.: 514 751-2003 ext. 236
E-mail: dbock@ambrilia.com

 

Zoladex® is a registered trademark of AstraZeneca PLC

 

Goserelin

Novel 1-month and 3-month formulations of goserelin

Indication

Hormone-sensitive prostate cancer and some gynecological indications

Development status

Phase I/II

Patents

Proprietary formulation

Partner

To be determined; Europe, Japan

Documentation